Insider · CIK 0001905248
Octavio Espinoza
Files at LGND (LIGAND PHARMACEUTICALS INC). First filing Feb 29, 2024, latest Aug 14, 2026.
In brief
Octavio Espinoza files SEC Form 4 as CFO at LGND (LIGAND PHARMACEUTICALS INC). Since Feb 29, 2024, Octavio Espinoza has reported 1 open-market buy worth $156k and 7 open-market sells worth $14M, the latest filed on Aug 14, 2026.
A track record needs three past buys with six months of prices behind them; Octavio Espinoza has 1, so none is measured yet.
The newest scored trade: sold $9.2M of LGND on Aug 12, 2026, filed Aug 14, 2026, scored 47 (moderate), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 4 sells worth $13M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
LGND: LIGAND PHARMACEUTICALS INC
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 47Moderate | LIGAND PHARMACEUTICALS INC | $9.2M 31,641 shares | -53% | +94% from low-9% from high | |
| 28Weak | LIGAND PHARMACEUTICALS INC | $688k 3,057 shares | -13% | +129% from low0% from high | |
| 37Weak | LIGAND PHARMACEUTICALS INC | $2.8M 13,423 shares | -38% | +116% from low-0% from high | |
| 45Moderate | LIGAND PHARMACEUTICALS INC | $340k 1,804 shares | -6% | +96% from low-9% from high | |
| 58Moderate | LIGAND PHARMACEUTICALS INC | $156k 1,500 shares | +6% | +8% from low-20% from high | |
| 46Moderate | LGNDsell LIGAND PHARMACEUTICALS INC | $575k 5,000 shares | -21% | - | |
| 35Weak | LGNDsell LIGAND PHARMACEUTICALS INC | $245k 2,104 shares | -9% | - | |
| 7Weak | LGNDsell LIGAND PHARMACEUTICALS INC | $12k 140 shares | -0% | +70% from low-5% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Aug 12, 2026 | LGND LIGAND PHARMACEUTICALS INCORPORATED | 31,641 0.16% of outstanding | $9.1M | Aug 12, 2026 | none |
| Mar 11, 2026 | LGND LIGAND PHARMACEUTICALS INC | 3,057 0.02% of outstanding | $649k | Mar 11, 2026 | $3.1M |
| Mar 4, 2026 | LGND LIGAND PHARMACEUTICALS INCORPORATED | 13,423 0.07% of outstanding | $2.7M | Mar 4, 2026 | none |
| Dec 12, 2025 | LGND LIGAND PHARMACEUTICALS INCORPORATED | 1,804 0.01% of outstanding | $340k | Dec 12, 2025 | none |
| Mar 4, 2025 | LGND LIGAND PHARMACEUTICALS INC | 5,000 0.03% of outstanding | $575k | Mar 4, 2025 | $245k |
| Dec 23, 2024 | LGND LIGAND PHARMACEUTICALS INC | 2,104 0.01% of outstanding | $245k | Dec 23, 2024 | none |
| Feb 28, 2024 | LGND LIGAND PHARMACEUTICALS INC | 27,725 0.10% of outstanding | $2.5M | Feb 28, 2024 | none |
Transactions
The newest 50 of 82 rows this insider has filed.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | LGND LIGAND PHARMACEUTICALS INC | MOption exercise Common Stock10b5-1 | +16,179 | $52.84 | $855k | 43,875 | Aug 14, 2026 |
| Aug 12, 2026 | LGND LIGAND PHARMACEUTICALS INC | MOption exercise Common Stock10b5-1 | +2,074 | $70.04 | $145k | 45,949 | Aug 14, 2026 |
| Aug 12, 2026 | LGND LIGAND PHARMACEUTICALS INC | MOption exercise Common Stock10b5-1 | +2,869 | $55.75 | $160k | 48,818 | Aug 14, 2026 |
| Aug 12, 2026 | LGND LIGAND PHARMACEUTICALS INC | MOption exercise Common Stock10b5-1 | +7,171 | $57.22 | $410k | 55,989 | Aug 14, 2026 |
| Aug 12, 2026 | LGND LIGAND PHARMACEUTICALS INC | MOption exercise Common Stock10b5-1 | +3,348 | $68.74 | $230k | 59,337 | Aug 14, 2026 |
| Aug 12, 2026 | LGND LIGAND PHARMACEUTICALS INC | SOpen-market sale Common Stock10b5-1 | -31,641 | $292.07 | $9.2M | 27,696 | Aug 14, 2026 |
| Aug 12, 2026 | LGND LIGAND PHARMACEUTICALS INC | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -2,869 | $0.00 | $0 | 0 | Aug 14, 2026 |
| Aug 12, 2026 | LGND LIGAND PHARMACEUTICALS INC | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -7,171 | $0.00 | $0 | 0 | Aug 14, 2026 |
| Aug 12, 2026 | LGND LIGAND PHARMACEUTICALS INC | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -16,179 | $0.00 | $0 | 0 | Aug 14, 2026 |
| Aug 12, 2026 | LGND LIGAND PHARMACEUTICALS INC | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -3,348 | $0.00 | $0 | 0 | Aug 14, 2026 |
| Aug 12, 2026 | LGND LIGAND PHARMACEUTICALS INC | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -2,074 | $0.00 | $0 | 0 | Aug 14, 2026 |
| Jun 30, 2026 | LGND LIGAND PHARMACEUTICALS INC | JOther Common Stock | +17 | $160.71 | $2,732 | 27,696 | Jul 6, 2026 |
| May 27, 2026 | LGND LIGAND PHARMACEUTICALS INC | MOption exercise Common Stock | +764 | $63.62 | $49k | 26,707 | May 28, 2026 |
| May 27, 2026 | LGND LIGAND PHARMACEUTICALS INC | MOption exercise Common Stock | +972 | $52.84 | $51k | 27,679 | May 28, 2026 |
| May 27, 2026 | LGND LIGAND PHARMACEUTICALS INC | MOption exercise Employee Stock Option (right to buy)derivative | -972 | $0.00 | $0 | 0 | May 28, 2026 |
| May 27, 2026 | LGND LIGAND PHARMACEUTICALS INC | MOption exercise Employee Stock Option (right to buy)derivative | -764 | $0.00 | $0 | 17,407 | May 28, 2026 |
| Mar 2, 2026 | LGND LIGAND PHARMACEUTICALS INC | AGrant or award Common Stock | +4,933 | $0.00 | $0 | 37,945 | Mar 27, 2026 |
| Mar 2, 2026 | LGND LIGAND PHARMACEUTICALS INC | AGrant or award Employee Stock Option (right to buy)derivative | +23,527 | $0.00 | $0 | 23,527 | Mar 27, 2026 |
| Mar 11, 2026 | LGND LIGAND PHARMACEUTICALS INC | MOption exercise Common Stock10b5-1 | +2,405 | $92.65 | $223k | 24,067 | Mar 13, 2026 |
| Mar 11, 2026 | LGND LIGAND PHARMACEUTICALS INC | SOpen-market sale Common Stock10b5-1 | -3,057 | $225.00 | $688k | 21,010 | Mar 13, 2026 |
| Mar 11, 2026 | LGND LIGAND PHARMACEUTICALS INC | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -2,405 | $0.00 | $0 | 0 | Mar 13, 2026 |
| Mar 4, 2026 | LGND LIGAND PHARMACEUTICALS INC | MOption exercise Common Stock10b5-1 | +1,607 | $58.49 | $94k | 34,619 | Mar 6, 2026 |
| Mar 4, 2026 | LGND LIGAND PHARMACEUTICALS INC | MOption exercise Common Stock10b5-1 | +466 | $80.72 | $38k | 35,085 | Mar 6, 2026 |
| Mar 4, 2026 | LGND LIGAND PHARMACEUTICALS INC | SOpen-market sale Common Stock10b5-1 | -699 | $198.71 | $139k | 34,386 | Mar 6, 2026 |
| Mar 4, 2026 | LGND LIGAND PHARMACEUTICALS INC | SOpen-market sale Common Stock10b5-1 | -53 | $200.08 | $11k | 34,333 | Mar 6, 2026 |
| Mar 4, 2026 | LGND LIGAND PHARMACEUTICALS INC | SOpen-market sale Common Stock10b5-1 | -698 | $201.09 | $140k | 33,635 | Mar 6, 2026 |
| Mar 4, 2026 | LGND LIGAND PHARMACEUTICALS INC | SOpen-market sale Common Stock10b5-1 | -950 | $201.73 | $192k | 32,685 | Mar 6, 2026 |
| Mar 4, 2026 | LGND LIGAND PHARMACEUTICALS INC | SOpen-market sale Common Stock10b5-1 | -697 | $202.79 | $141k | 31,988 | Mar 6, 2026 |
| Mar 4, 2026 | LGND LIGAND PHARMACEUTICALS INC | SOpen-market sale Common Stock10b5-1 | -668 | $203.63 | $136k | 31,320 | Mar 6, 2026 |
| Mar 4, 2026 | LGND LIGAND PHARMACEUTICALS INC | SOpen-market sale Common Stock10b5-1 | -743 | $204.74 | $152k | 30,577 | Mar 6, 2026 |
| Mar 4, 2026 | LGND LIGAND PHARMACEUTICALS INC | SOpen-market sale Common Stock10b5-1 | -1,457 | $205.79 | $300k | 29,120 | Mar 6, 2026 |
| Mar 4, 2026 | LGND LIGAND PHARMACEUTICALS INC | SOpen-market sale Common Stock10b5-1 | -1,588 | $206.89 | $329k | 27,532 | Mar 6, 2026 |
| Mar 4, 2026 | LGND LIGAND PHARMACEUTICALS INC | SOpen-market sale Common Stock10b5-1 | -2,457 | $207.91 | $511k | 25,075 | Mar 6, 2026 |
| Mar 4, 2026 | LGND LIGAND PHARMACEUTICALS INC | SOpen-market sale Common Stock10b5-1 | -3,413 | $208.80 | $713k | 21,662 | Mar 6, 2026 |
| Mar 4, 2026 | LGND LIGAND PHARMACEUTICALS INC | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -1,607 | $0.00 | $0 | 0 | Mar 6, 2026 |
| Mar 4, 2026 | LGND LIGAND PHARMACEUTICALS INC | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -466 | $0.00 | $0 | 0 | Mar 6, 2026 |
| Feb 14, 2026 | LGND LIGAND PHARMACEUTICALS INC | AGrant or award Common Stock | +7,390 | $0.00 | $0 | 35,965 | Feb 18, 2026 |
| Feb 14, 2026 | LGND LIGAND PHARMACEUTICALS INC | FTax withholding Common Stock | -3,761 | $183.83 | $691k | 32,204 | Feb 18, 2026 |
| Feb 14, 2026 | LGND LIGAND PHARMACEUTICALS INC | AGrant or award Common Stock | +8,810 | $0.00 | $0 | 41,014 | Feb 18, 2026 |
| Feb 14, 2026 | LGND LIGAND PHARMACEUTICALS INC | FTax withholding Common Stock | -4,483 | $183.83 | $824k | 36,531 | Feb 18, 2026 |
| Feb 15, 2026 | LGND LIGAND PHARMACEUTICALS INC | FTax withholding Common Stock | -1,026 | $183.83 | $189k | 35,505 | Feb 18, 2026 |
| Feb 15, 2026 | LGND LIGAND PHARMACEUTICALS INC | FTax withholding Common Stock | -1,223 | $183.83 | $225k | 34,282 | Feb 18, 2026 |
| Feb 15, 2026 | LGND LIGAND PHARMACEUTICALS INC | FTax withholding Common Stock | -1,270 | $183.83 | $233k | 33,012 | Feb 18, 2026 |
| Dec 31, 2025 | LGND LIGAND PHARMACEUTICALS INC | JOther Common Stock | +8 | $95.68 | $765 | 28,575 | Jan 6, 2026 |
| Dec 16, 2025 | LGND LIGAND PHARMACEUTICALS INC | MOption exercise Common Stock | +1,194 | $52.84 | $63k | 27,380 | Dec 18, 2025 |
| Dec 16, 2025 | LGND LIGAND PHARMACEUTICALS INC | MOption exercise Common Stock | +69 | $57.22 | $3,948 | 27,449 | Dec 18, 2025 |
| Dec 16, 2025 | LGND LIGAND PHARMACEUTICALS INC | MOption exercise Common Stock | +285 | $63.62 | $18k | 27,734 | Dec 18, 2025 |
| Dec 16, 2025 | LGND LIGAND PHARMACEUTICALS INC | MOption exercise Common Stock | +652 | $92.65 | $60k | 28,386 | Dec 18, 2025 |
| Dec 16, 2025 | LGND LIGAND PHARMACEUTICALS INC | MOption exercise Common Stock | +181 | $103.42 | $19k | 28,567 | Dec 18, 2025 |
| Dec 16, 2025 | LGND LIGAND PHARMACEUTICALS INC | MOption exercise Employee Stock Option (right to buy)derivative | -1,194 | $0.00 | $0 | 972 | Dec 18, 2025 |
Questions about Octavio Espinoza
Answered from the filings on this page, as of the latest one.
Is Octavio Espinoza buying or selling?
In the last 12 months Octavio Espinoza reported 0 open-market buys worth $0 and 4 open-market sells worth $13M on SEC Form 4; the latest was sold $9.2M of LGND on Aug 12, 2026. Grants, option exercises and tax withholding are not counted.
How did Octavio Espinoza's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Octavio Espinoza has 1.
Where does Octavio Espinoza file Form 4?
Octavio Espinoza has filed Form 4 at LGND (LIGAND PHARMACEUTICALS INC) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.